This federal Project Grant award from the Department of the Army Medical Command (CFDA 12.420 - Military Medical Research and Development) provides $1,348,041.00 to the Regents of the University of Minnesota to develop a RET-specific proteomic assay from circulating tumor cells in lethal prostate cancer. The award began on Mar 1, 2024 and is scheduled for completion by Feb 28, 2027. This research aims to transform health care for military service members and the general public through innovative and impactful work in the area of cancer diagnostics and treatment. As a major land-grant research university, the University of Minnesota leverages its extensive research capabilities, faculty expertise, and institutional partnerships to deliver cutting-edge biomedical research for federal agencies addressing critical military and public health priorities.
Generated 11/26/24, 2:19 AM